两种药物治疗宫颈HR-HPV持续感染的疗效比较

发布时间：2018-08-18 20:42

【摘要】：目的比较抗HPV生物蛋白敷料及重组人干扰素α-2b凝胶治疗宫颈高危型人乳头瘤病毒持续感染的疗效。方法选取2014年10月-2016年2月期间在遵义医学院附院诊断宫颈HR-HPV持续感染患者共80例,采用计算机随机法按1:1比例抽取同期病例,分为A组(抗HPV生物蛋白敷料组)及B组(重组人干扰素α-2b凝胶组)各40例。均在治疗结束后第3个月、6个月及9个月复查高危HPV-DNA分型检测,若仍有HR-HPV感染则复查阴道镜。治疗结束后第9个月时,对两组治疗前液基细胞学、阴道镜结果异常者给予复查。比较两组治疗后HR-HPV的转阴率,液基细胞学、阴道镜检查及病理学结果变化,药物不良反应。结果1.宫颈HR-HPV持续感染患者中在31-50岁占76.25%。2.单一HR-HPV持续感染的主要型别为16、58及52型(P0.005),混合型感染主要为52型合并其他型感染(P0.05)。3.A组治疗结束后第3、6、9个月的HR-HPV转阴率分别为30.00%、50.00%及60.00%,B组分别为10.00%、25%及37.5%,两组间同一时间点HR-HPV转阴率比较均有统计学意义(P均0.05);两组治疗后第9个月的HR-HPV转阴率均高于同组别第3个月(P均0.05)。4.两组治疗前后液基细胞学检查及阴道镜检查的差异均无统计学意义(P均0.05)。5.两组均无严重药物不良反应发生。结论抗HPV生物蛋白敷料对宫颈HR-HPV持续感染的疗效优于重组人干扰素α-2b凝胶。
[Abstract]:Objective to compare the efficacy of anti-HPV bioprotein dressing and recombinant human interferon-伪-2b gel in the treatment of high risk human papillomavirus infection. Methods A total of 80 patients with persistent cervical HR-HPV infection were selected from October 2014 to February 2016 in the affiliated Hospital of Zunyi Medical College. Group A (anti HPV bioprotein dressing group) and group B (recombinant human interferon 伪-2b gel group) were divided into two groups: group A (40 cases) and group B (40 cases of recombinant human interferon 伪-2b gel). High risk HPV-DNA typing was detected at 3 months, 6 months and 9 months after treatment, and colposcopy if there was still HR-HPV infection. At the 9th month after treatment, the patients with abnormal cytology and colposcopy before treatment were reviewed. The conversion rate of HR-HPV, liquid-based cytology, colposcopy, pathological changes and adverse drug reactions were compared between the two groups. Result 1. Among the patients with persistent cervical HR-HPV infection, 76.25% were 31 to 50 years old. The main types of persistent infection of single HR-HPV were 160.58 and 52 (P0.005), the main types of mixed infection were 52 combined with other types of infection (P0.05) .3.A group (P0.05). The negative rate of HR-HPV in group A was 30.0050.005% and 60.005% at 9 months after treatment, and it was 10.0025% and 37.5% in group B, respectively, at the same time between the two groups. The negative rate of HR-HPV in the two groups was significantly higher than that in the same group at the 9th month after treatment (P 0.05). There was no significant difference between the two groups in liquid based cytology and colposcopy before and after treatment (P 0.05). No serious adverse drug reactions occurred in both groups. Conclusion the effect of anti-HPV bioprotein dressing on persistent cervical HR-HPV infection is better than that of recombinant human interferon-伪-2b gel.
【学位授予单位】：遵义医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.33

【相似文献】